A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874)

🧪 Interventions in This Study

• GDC-6036 (DRUG)
• Atezolizumab (DRUG)
• Cetuximab (DRUG)
• Bevacizumab (DRUG)
• Erlotinib (DRUG)
• GDC-1971 (DRUG)
• Inavolisib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (63 Sites)

Showing the first 25 of 63 sites.

• City of Hope Comprehensive Cancer Center — Duarte, California
• UCSD Moores Cancer Center — La Jolla, California
• Chao Family Comprehensive Cancer Center UCI — Orange, California
• Yale Cancer Center — New Haven, Connecticut
• Florida Cancer Specialists - Sarasota — Sarasota, Florida
• Dana Farber Cancer Institute — Boston, Massachusetts
• Memorial Sloan Kettering Cancer Center — New York, New York
• University of Oklahoma — Oklahoma City, Oklahoma
• UPMC - Hillman Cancer Center — Pittsburgh, Pennsylvania
• Slade Health Inward goods — Mount Kuring-Gai, New South Wales
• Peter MacCallum Cancer Center — Melbourne, Victoria
• Alfred Health — Melbourne, Victoria
• Linear Clinical Research Limited — Nedlands, Western Australia
• UZ Antwerpen — Edegem,
• CHU de Liège — Liège,
• AZ St Maarten Campus Leopoldstr — Mechelen,
• Santa Casa de Misericordia de Belo Horizonte - PPDS — Belo Horizonte, Minas Gerais
• Hospital Erasto Gaertner — Curitiba, Paraná
• Hospital de Clinicas de Porto Alegre HCPA PPDS — Porto Alegre, Pará
• Universidade de Caxias do Sul — Caxias do Sul, Rio Grande do Sul
• Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS) — Porto Alegre, Rio Grande do Sul
• Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS — São José do Rio Preto, São Paulo
• Instituto Nacional de Câncer — Rio de Janeiro,
• Ottawa Hospital — Ottawa, Ontario
• Princess Margaret Cancer Centre — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona

Explore by condition: All Non-Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.